InvestSMART

Osteopore Limited (ASX:OSX)

ALERT: Price-sensitive ASX Announcement for OSX
Current share price for OSX : $0.005 0.001 (11.11%)+
Release
23 Jun 2026 8:51AM
Price at Release
$0.005
Full Release
download
Summary
Osteopore Limited, a leader in 3D-printed biomimetic and bioresorbable implants, announced a further drawdown of Tranche 2 of their Redeemable Convertible Notes. The company entered into a subscription agreement with Advance Opportunities Fund in December 2024, planning to issue up to A$20 million in notes across four tranches. The latest subscription by the fund includes sub-tranche ST04 of T2 notes valued at A$250,000. The funds raised will support Osteopore's ongoing business activities and future projects. This strategic financial move reinforces their commitment to innovative regenerative medicine solutions.
Key Points
  • Further drawdown of Tranche 2 of Redeemable Convertible Notes
  • Subscription agreement with Advance Opportunities Fund
  • Total nominal value of notes up to A$20 million
  • New sub-tranche ST04 of T2 notes issued
  • Aggregate nominal amount of A$250,000 for ST04
  • Funds to support business and future developments
  • Osteopore specializes in 3D-printed biomimetic implants
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.